Literature DB >> 17931754

C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei.

Elke S Bergmann-Leitner1, Elizabeth H Duncan, Wolfgang W Leitner, Albert Neutzner, Tatyana Savranskaya, Evelina Angov, George C Tsokos.   

Abstract

Immune response against circumsporozoite protein (CSP) of Plasmodium berghei, a major surface protein on the sporozoite, confers protection in various murine malaria models. Engineered DNA vaccine encoding CSP and 3 copies of C3d caused an unexpected loss in protection attributed to the binding of C3d to the C-terminal region of CSP. Because the C3d region known as p28 represents the complement receptor (CR) 2-binding motif, we developed a CSP-3 copies of p28 DNA construct (CSP-3p28). CSP-3p28-immunized mice were better protected against P. berghei sporozoites than CSP-immunized mice 6 weeks after the 2nd boost, produced sufficient IgG1 anti-CSP and CSP C-terminus antibody and failed to produce IgG2a. CSP-3C3d-immunized mice were not protected, failed to produce IgG1 and produced high amounts of IgG2a. We conclude that use of the CR2-binding motif of C3d as molecular adjuvant to CSP results in anti-malaria protective immune response probably by targeting the chimeric protein to CR2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17931754     DOI: 10.1016/j.vaccine.2007.08.030

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  Therapeutic potential of complement modulation.

Authors:  Eric Wagner; Michael M Frank
Journal:  Nat Rev Drug Discov       Date:  2009-12-04       Impact factor: 84.694

2.  Adjuvant-like effect of vaccinia virus 14K protein: a case study with malaria vaccine based on the circumsporozoite protein.

Authors:  Aneesh Vijayan; Carmen E Gómez; Diego A Espinosa; Alan G Goodman; Lucas Sanchez-Sampedro; Carlos Oscar S Sorzano; Fidel Zavala; Mariano Esteban
Journal:  J Immunol       Date:  2012-05-21       Impact factor: 5.422

3.  Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy.

Authors:  Wolfgang W Leitner; Elke S Bergmann-Leitner; Evelina Angov
Journal:  Malar J       Date:  2010-05-27       Impact factor: 2.979

4.  Deletion of the complement phagocytic receptors CR3 and CR4 does not alter susceptibility to experimental cerebral malaria.

Authors:  T N Ramos; D C Bullard; S R Barnum
Journal:  Parasite Immunol       Date:  2012-11       Impact factor: 2.280

5.  Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens.

Authors:  Benjamin J Read; Lori Won; John C Kraft; Isaac Sappington; Aereas Aung; Shengwei Wu; Julia Bals; Chengbo Chen; Kelly K Lee; Daniel Lingwood; Neil P King; Darrell J Irvine
Journal:  Cell Rep       Date:  2022-01-11       Impact factor: 9.423

6.  Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.

Authors:  Elke S Bergmann-Leitner; Elizabeth H Duncan; Ryan M Mease; Evelina Angov
Journal:  Malar J       Date:  2012-09-07       Impact factor: 2.979

7.  A new DNA vaccine fused with the C3d-p28 induces a Th2 immune response against amyloid-beta.

Authors:  Wanshu Guo; Sha Sha; Tongzi Jiang; Xiaona Xing; Yunpeng Cao
Journal:  Neural Regen Res       Date:  2013-09-25       Impact factor: 5.135

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.